Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Figures corrected afterwards (2024).
Gross margin
€ 4.2 million
▲ 5% vs 2024
Profit
Caution€ -5.8 million
▼ 20% vs 2024
Debts
Low€ 5.6 million
▼ 5% vs 2024
EPICS THERAPEUTICS from Charleroi, company number BE0690759071, closed financial year 2025 with a result of € -5.8 million after tax. For that financial year EPICS THERAPEUTICS recorded a gross margin of € 4.2 million and equity of € 9.1 million. Compared with financial year 2024, the result moved from € -4.8 million to € -5.8 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
What happened at EPICS THERAPEUTICS?
What happened at EPICS THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Newton Biocapital Partners SRL stepped down as director. NBB
- JCO Consulting SRL stepped down as director. NBB
- JUNOMATI BV stepped down as director. NBB
- Sparaxis SA stepped down as director. NBB
- EJM Consulting stepped down as director. NBB
- SFPI SA stepped down as director. NBB
- Graeme Fraser stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 5.8 million. Source: NBB ↗
In short
From € 4.6 million loss in 2021 to € 5.8 million loss in 2025.
On average € 131,500 of value added per employee in 2025.
A new publication or filing at EPICS THERAPEUTICS? We notify you, reason included.
Follow EPICS THERAPEUTICSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Chairman of the board · represented by Michel Allé
Also active at: D'Ieteren Group, EURVEST, NEUVASQ BIOTECHNOLOGIES +2 more
since 2019 · until 2025
Newton Biocapital Partners SRL
Director · represented by Alain Parthoens
Also active at: SYNERGIA MEDICAL, Newton Biocapital I, pricaf privée de droit belge, Newton Biocapital I Investment Pool +4 more
since 2025 · until 2030
Director · represented by Jean Combalbert
Also active at: Newton Biocapital I, pricaf privée de droit belge, THERAtRAME
since 2025 · until 2030
since 2025 · until 2030
Director · represented by Caroline Thielen
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more
since 2025 · until 2030
EJM Consulting
Director · represented by Elisabeth Svanberg
since 2025 · until 2030
Director · represented by Francois Fontaine
Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale +62 more
since 2025 · until 2030
Graeme Fraser
Managing director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Rue Adrienne Bolland 47
6041 Charleroi
Rue Auguste Piccard 48
6041 Charleroi
Active since 20 February 2018
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
Domain
Domain
epicstherapeutics.com
Registered
2017-07-15
Registrar
EuroDNS S.A.
Expires
2026-07-15
Website info
Features
Security
Network
Details
- Company number
- 0690.759.071
- VAT number
- BE 0690.759.071
- Registered office
- Rue Adrienne Bolland 47, 6041 Charleroi
- Names & denominations
- EPICS THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 February 2018
- Peppol
- Active · Active since 8 Sept 2025
- Contact
- epicstherapeutics.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van geneesmiddelen